A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-118 in Healthy Adult Subjects
Latest Information Update: 07 Jun 2024
At a glance
- Drugs VX 118 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 31 May 2024 Status changed from active, no longer recruiting to completed.
- 09 May 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2024 Status changed from not yet recruiting to recruiting.